Mask wearers have become a common sight during the Covid-19 pandemic. While it makes sense to assume that the measures to prevent the coronavirus from spreading also hinders other diseases, the reality might be a bit more complicated, argue experts.

Image source: Unsplash/Gayatri Malhotra

Masks & social distancing

Do Covid countermeasures also curb other diseases? It's not quite that simple

Measures to reduce the spread of Covid-19 through non-pharmaceutical interventions (NPIs) such as mask wearing and social distancing are a key tool in combatting the impact of the ongoing coronavirus pandemic.

These actions also have greatly reduced incidence of many other diseases, including influenza and respiratory syncytial virus (RSV). Current reductions in these common respiratory infections, however, may merely postpone the incidence of future outbreaks, according to a study by Princeton University researchers published in the Proceedings of the National Academy of Sciences. “Declines in case numbers of several respiratory pathogens have been observed recently in many global locations,” said first author Rachel Baker, an associate research scholar at the High Meadows Environmental Institute (HMEI) at Princeton University.

Recommended article

Photo

COVID-19 video

Coughing visualization shows benefits of wearing a good mask

Coupling function with fashion, cloth and home-sewn face masks are available in a variety of forms and fabrics. While experts underscore that wearing a mask is effective in helping to prevent the spread of COVID-19, not all masks — or the materials with which they’re made — contain virus particles equally. In a new video, University of Wisconsin–Madison engineer Scott Sanders demonstrates…

“While this reduction in cases could be interpreted as a positive side effect of Covid-19 prevention, the reality is much more complex,” Baker said. “Our results suggest that susceptibility to these other diseases, such as RSV and flu, could increase while NPIs are in place, resulting in large outbreaks when they begin circulating again.”

Baker and her co-authors found that NPIs could lead to a future uptick in RSV — an endemic viral infection in the United States and a leading cause of lower respiratory-tract infections in young infants — but that the same effect was not as pronounced for influenza. “Although the detailed trajectory of both RSV and influenza in the coming years will be complex, there are clear and overarching trends that emerge when one focuses on some essential effects of NPIs and seasonality on disease dynamics,” said co-author Gabriel Vecchi, Princeton professor of geosciences and the High Meadows Environmental Institute.

The researchers used an epidemiological model based on historic RSV data and observations of the recent decline in RSV cases to examine the possible impact of Covid-19 NPIs on future RSV outbreaks in the United States and Mexico. They found that even relatively short periods of NPI measures could lead to large future RSV outbreaks. These outbreaks were often delayed following the end of the NPI period, with peak cases projected to occur in many locations in winter 2021-22.  “It is very important to prepare for this possible future outbreak risk and to pay attention to the full gamut of infections impacted by Covid-19 NPIs,” Baker said.

NPIs could have unintended longer-term impacts on the dynamics of other diseases that are similar to the impact on susceptibility we projected for RSV

Bryan Grenfell

The authors also considered the implications of Covid-19 NPIs for seasonal influenza outbreaks and found results qualitatively similar to RSV. The dynamics of influenza are much harder to project due to viral evolution, however, which drives uncertainty over future circulating strains and the efficacy of available vaccines. “For influenza, vaccines could make a big difference,” Baker said. “In addition, the impact of NPIs on influenza evolution is unclear but potentially very important.” 

“The decrease in cases of influenza and RSV — as well as the possible future increase we project — is arguably the broadest global impact of NPIs across a variety of human diseases that we’ve seen,” said co-author Bryan Grenfell, the Kathryn Briger and Sarah Fenton Professor of Ecology and Evolutionary Biology and Public Affairs, who is associated faculty in HMEI. “NPIs could have unintended longer-term impacts on the dynamics of other diseases that are similar to the impact on susceptibility we projected for RSV,” he said.

A similar effect of pandemic-related NPIs on other pathogens was observed following the 1918 influenza pandemic. Historic measles data from London show a shift from annual cycles to biennial outbreaks following a period of control measures implemented at that time.  

Co-author C. Jessica Metcalf, associate professor of ecology and evolutionary biology and public affairs and an associated faculty member in HMEI, said that directly evaluating the associated risks of NPIs by developing and deploying tools such as serology that would better measure susceptibility is an important public health and policy direction. “The future repercussions of NPIs revealed by this paper hinge on how these measures change the landscape of immunity and susceptibility,” Metcalf said.


Source: Princeton University

14.11.2020

Read all latest stories

Related articles

Photo

Austrian study

Insights into transmission of SARS-CoV-2

In the COVID-19 pandemic, 57 million people have already been infected worldwide. In the search for vaccines and therapies, a precise understanding of the virus, its mutations and transmission…

Photo

Among trillion possibilities

Rapid method finds potent COVID-19 antibody

University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.

Photo

Flaws in study design

Will COVID-19 vaccines save lives? Right now, we cannot tell

Vaccines are being hailed as the solution to the COVID-19 pandemic, but the vaccine trials currently underway are not designed to tell us if they will save lives, reports Peter Doshi, Associate…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH